Phase 3 N=25,871 Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure
Heart Failure
Primary: Number of Participants With New Heart Failure Hospitalization — 240; 259; 244; 255 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Kidney Cancer
Primary: Best Response as Measured by CT, Bone Scans, and Clinical Progression — 1; 0; 0; 1 Participants
Phase 3 N=35 Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Peak Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Within 4 Hours Post-dose Following 1 Week of Treatment — 0.256; 0.274 L — p=0.3450
Phase 4 N=30 Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
Erythematotelangiectatic Rosacea
Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale
N/A N=80 Integrative Couple Treatment for Pathological Gambling
Pathological Gambling
Primary: Gambling Symptom Assessment Scale (G-SAS) — 18.52; 16.66; 6.85; 12.39 score on a scale
N/A N=72 Battlefield Acupuncture and Its Use In Multimodal Perioperative Anesthesia Care
Acupuncture, Ear
Primary: Postoperative Opioid Consumption — 18.3; 38.6 Morphine Milligram Equivalent
Phase 3 N=170 Rituximab Vasculitis Maintenance Study
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Microscopic Polyangiitis · Wegener Granulomatosis
Primary: Relapse-free Survival — 38; 60; 13; 32 participants
Phase 3 N=78 Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
Liver Cancer
Primary: Percentage of Patients With Occurrence of Severe Bleeding and/or Liver Failure — 5.88; 2.78 percentage of participants
Phase 2 N=24 Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
Asthma
Primary: Area Under the Curve of Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14 — -0.53…
Phase 3 N=70 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
Mydriasis
Primary: Change in Pupil Diameter From Baseline — 4.747; 4.779; 0.134; 0.032 millimeters
Phase 2 N=80 Brexpiprazole in Borderline Personality Disorder
Borderline Personality Disorder
Primary: Zanarini Rating Scale for Borderline Personality Disorder — 14.9; 14.9; 7.6; 6.7 score on a scale
Phase 1 N=48 A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Acute Myeloid Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy Cohort — 0; 0; 0 Participants
Phase 3 N=64 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
Mydriasis
Primary: Change in Pupil Diameter From Baseline — 2.672; 2.583; 2.657; 2.569 millimeters
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
N/A N=47 Text2Connect, Component 2 of iCHART (Integrated Care to Help At-Risk Teens)
Depression · Suicidal Ideation
Primary: Attendance to Treatment — 22; 0; 20; 4 Participants